The p38 mitogen-activated protein kinase (MAPK) signaling pathway, a cascade contributing to neuroinflammation, could play a key role in AD pathophysiology, and preclinical and clinical trials have evaluated the pharmacological effects of p38 MAPKα inhibitors in the brain (8, 9). This evidence concerns the gene MAPK14 and Alzheimer disease.